治疗遗传性骨病在研药物临床试验失败 Ultragenyx Pharmaceutical(RARE.US)盘前暴跌超42%

Core Viewpoint - Ultragenyx Pharmaceutical's stock price plummeted over 42% to $19.69 following the announcement that its investigational drug for a specific genetic bone disease did not meet its primary efficacy endpoint in late-stage clinical trials [1] Group 1 - The stock price of Ultragenyx Pharmaceutical (RARE.US) experienced a significant decline, dropping more than 42% [1] - As of the report, the stock was trading at $19.69 [1] - The decline was triggered by the failure of a key investigational drug in late-stage clinical trials [1]